Dorothy Engelking

Dorothy Engelking formerly worked at Actavis, Inc., as Vice President-Regulatory Affairs from 1999 to 2006, Kendle International LLC, as Vice President-Global Regulatory Affairs from 2008 to 2009, Adamas Pharmaceuticals LLC, as VP-Regulatory Affairs & Quality Assurance from 2019 to 2021, Xanodyne Pharmaceuticals, Inc., as Senior Vice President-Regulatory Affairs from 2006 to 2008, Neos Therapeutics, Inc., as Vice President-Regulatory Affairs, and DURECT Corp., as Vice President-Regulatory Affairs from 2022 to 2025.
Ms. Engelking received her undergraduate degree and graduate degree from South Dakota School of Mines & Technology.